Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. 2018

Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
Medicinal Chemistry Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco. Khalid.karrouchi@um5s.net.ma.

Pyrazole and its derivatives are considered a pharmacologically important active scaffold that possesses almost all types of pharmacological activities. The presence of this nucleus in pharmacological agents of diverse therapeutic categories such as celecoxib, a potent anti-inflammatory, the antipsychotic CDPPB, the anti-obesity drug rimonabant, difenamizole, an analgesic, betazole, a H2-receptor agonist and the antidepressant agent fezolamide have proved the pharmacological potential of the pyrazole moiety. Owing to this diversity in the biological field, this nucleus has attracted the attention of many researchers to study its skeleton chemically and biologically. This review highlights the different synthesis methods and the pharmacological properties of pyrazole derivatives. Studies on the synthesis and biological activity of pyrazole derivatives developed by many scientists around the globe are reported.

UI MeSH Term Description Entries
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019440 Anti-Obesity Agents Agents that increase energy expenditure and weight loss by neural and metabolic regulation. Anti-Obesity Agent,Anti-Obesity Drug,Antiobesity Agent,Antiobesity Drug,Weight-Loss Agents,Weight-Loss Drug,Anti-Obesity Drugs,Antiobesity Agents,Antiobesity Drugs,Weight-Loss Drugs,Agent, Anti-Obesity,Agent, Antiobesity,Agents, Anti-Obesity,Agents, Antiobesity,Agents, Weight-Loss,Anti Obesity Agent,Anti Obesity Agents,Anti Obesity Drug,Anti Obesity Drugs,Drug, Anti-Obesity,Drug, Antiobesity,Drug, Weight-Loss,Drugs, Anti-Obesity,Drugs, Antiobesity,Drugs, Weight-Loss,Weight Loss Agents,Weight Loss Drug,Weight Loss Drugs

Related Publications

Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
March 2017, Molecules (Basel, Switzerland),
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
May 2011, European journal of medicinal chemistry,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
September 2014, Molecules (Basel, Switzerland),
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
September 2022, RSC advances,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
November 2008, Journal of agricultural and food chemistry,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
January 2008, Pakistan journal of pharmaceutical sciences,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
June 2002, Biological & pharmaceutical bulletin,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
September 1967, Il Farmaco; edizione scientifica,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
June 2023, ACS omega,
Khalid Karrouchi, and Smaail Radi, and Youssef Ramli, and Jamal Taoufik, and Yahia N Mabkhot, and Faiz A Al-Aizari, and M'hammed Ansar
January 1982, Agents and actions. Supplements,
Copied contents to your clipboard!